Eventide Asset Management - Q1 2022 holdings

$6.38 Billion is the total value of Eventide Asset Management's 136 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 14.3% .

 Value Shares↓ Weighting
PANW BuyPALO ALTO NETWORKS INC$125,303,000
+48.1%
201,287
+32.4%
1.96%
+81.6%
TT BuyTRANE TECHNOLOGIES PLC$113,288,000
-23.5%
741,900
+1.2%
1.78%
-6.2%
GNRC BuyGENERAC HLDGS INC$110,610,000
-14.6%
372,100
+1.1%
1.73%
+4.7%
ENTG BuyENTEGRIS INC$108,526,000
+8.8%
826,800
+14.9%
1.70%
+33.4%
KNBE BuyKNOWBE4 INCcl a$96,960,000
+46.5%
4,211,983
+45.9%
1.52%
+79.6%
GH BuyGUARDANT HEALTH INC$86,966,000
-1.9%
1,312,900
+48.2%
1.36%
+20.3%
APTV BuyAPTIV PLC$86,155,000
-2.7%
719,700
+34.0%
1.35%
+19.3%
GLBE BuyGLOBAL E ONLINE LTD$84,294,000
-37.9%
2,495,391
+16.6%
1.32%
-23.8%
SPT BuySPROUT SOCIAL INC$84,121,000
-6.9%
1,049,943
+5.4%
1.32%
+14.2%
DDOG BuyDATADOG INC$74,978,000
-13.9%
495,000
+1.2%
1.18%
+5.6%
COUR BuyCOURSERA INC$57,351,000
+35.0%
2,489,174
+43.2%
0.90%
+65.6%
MPWR BuyMONOLITHIC PWR SYS INC$57,236,000
+36.2%
117,848
+38.4%
0.90%
+67.0%
CWEN BuyCLEARWAY ENERGY INCcl c$55,853,000
+4.5%
1,529,800
+3.1%
0.88%
+28.1%
A BuyAGILENT TECHNOLOGIES INC$54,308,000
-9.6%
410,400
+9.1%
0.85%
+10.8%
CLDX BuyCELLDEX THERAPEUTICS INC NEW$49,241,000
+2.9%
1,445,700
+16.7%
0.77%
+26.1%
PRAX BuyPRAXIS PRECISION MEDICINES I$44,873,000
-40.2%
4,395,000
+15.3%
0.70%
-26.7%
REXR BuyREXFORD INDL RLTY INC$44,530,000
+85.9%
597,000
+102.1%
0.70%
+128.1%
XMTR BuyXOMETRY INC$44,102,000
-9.8%
1,200,052
+25.8%
0.69%
+10.6%
LNG BuyCHENIERE ENERGY INC$40,541,000
+506.5%
292,400
+343.7%
0.64%
+647.1%
SMAR BuySMARTSHEET INC$38,182,000
-27.3%
697,000
+2.8%
0.60%
-10.9%
BPMC BuyBLUEPRINT MEDICINES CORP$37,849,000
-10.7%
592,500
+49.7%
0.59%
+9.4%
MRTX BuyMIRATI THERAPEUTICS INC$37,310,000
-12.8%
453,781
+55.6%
0.58%
+6.9%
ZYME BuyZYMEWORKS INC$35,240,000
-23.7%
5,380,200
+90.8%
0.55%
-6.4%
ZNTL BuyZENTALIS PHARMACEUTICALS INC$35,113,000
-21.0%
761,000
+43.9%
0.55%
-3.2%
KURA BuyKURA ONCOLOGY INC$33,142,000
+73.9%
2,061,044
+51.4%
0.52%
+113.6%
NVT BuyNVENT ELECTRIC PLC$30,697,000
-2.9%
882,600
+6.1%
0.48%
+19.1%
IMVT BuyIMMUNOVANT INC$29,603,000
-29.8%
5,372,512
+8.5%
0.46%
-13.9%
COGT BuyCOGENT BIOSCIENCES INC$29,211,000
-3.1%
3,900,000
+11.0%
0.46%
+19.0%
ENPH BuyENPHASE ENERGY INC$29,070,000
+138.9%
144,069
+116.6%
0.46%
+193.5%
STE BuySTERIS PLC$27,123,000
+13.7%
112,185
+14.5%
0.42%
+39.3%
PLD BuyPROLOGIS INC.$26,999,000
-0.1%
167,200
+4.1%
0.42%
+22.3%
EPIX BuyESSA PHARMA INC$25,772,000
-45.3%
4,170,259
+25.7%
0.40%
-32.9%
KLAC BuyKLA CORP$24,683,000
+0.6%
67,428
+18.2%
0.39%
+23.6%
SNPS BuySYNOPSYS INC$24,348,000
+44.4%
73,057
+59.7%
0.38%
+77.2%
NDAQ BuyNASDAQ INC$22,097,000
-0.7%
124,000
+17.0%
0.35%
+21.8%
WMB BuyWILLIAMS COS INC$21,853,000
+190.5%
654,100
+126.4%
0.34%
+256.2%
ESI BuyELEMENT SOLUTIONS INC$21,265,000
-6.2%
971,000
+4.0%
0.33%
+14.8%
PNR BuyPENTAIR PLC$18,995,000
-20.4%
350,400
+7.2%
0.30%
-2.3%
FRC BuyFIRST REP BK SAN FRANCISCO C$17,572,000
-10.3%
108,400
+14.2%
0.28%
+10.0%
NewNCINO INC$17,056,000416,200
+100.0%
0.27%
WD NewWALKER & DUNLOP INC$15,781,000121,935
+100.0%
0.25%
AESC BuyAES CORPunit 99/99/9999$14,948,000
+26.0%
151,100
+22.2%
0.23%
+53.9%
WEC NewWEC ENERGY GROUP INC$14,512,000145,400
+100.0%
0.23%
SYY BuySYSCO CORP$13,170,000
+27.6%
161,298
+22.8%
0.21%
+56.1%
ICPT BuyINTERCEPT PHARMACEUTICALS IN$13,016,000
+144.0%
800,000
+144.3%
0.20%
+200.0%
APTVPRA NewAPTIV PLC5.5% cnv pfd a$12,932,00094,500
+100.0%
0.20%
TRGP NewTARGA RES CORP$11,071,000146,700
+100.0%
0.17%
EGP BuyEASTGROUP PPTYS INC$10,327,000
+50.1%
50,800
+68.2%
0.16%
+84.1%
ANNX BuyANNEXON INC$9,900,000
-69.8%
3,626,508
+27.2%
0.16%
-62.9%
BuyROIVANT SCIENCES LTD$8,177,000
+22.0%
1,690,300
+141.5%
0.13%
+48.8%
ARE BuyALEXANDRIA REAL ESTATE EQ IN$6,782,000
+42.8%
33,700
+58.2%
0.11%
+73.8%
PHVS BuyPHARVARIS N V$5,659,000
+46.0%
302,619
+23.6%
0.09%
+78.0%
MNDY NewMONDAY COM LTD$5,137,00032,500
+100.0%
0.08%
NewENPHASE ENERGY INCnote 3/0$4,554,0004,463,000
+100.0%
0.07%
FRLN BuyFREELINE THERAPEUTICS HLDGSsponsored ads$3,970,000
-41.2%
3,606,192
+3.5%
0.06%
-27.9%
BuyARTERIS INC$2,522,000
-33.7%
194,000
+7.6%
0.04%
-18.4%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-05-16
Signatures

The EDGAR filing(s) were signed by:

About Eventide Asset Management

Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.

The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.

The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.

Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.

Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LOWES COS INC40Q3 20233.2%
PALO ALTO NETWORKS INC40Q3 20233.6%
ASML HOLDINGS NV40Q3 20231.9%
NEUROCRINE BIOSCIENCES INC40Q3 20231.1%
REPLIGEN CORP40Q3 20230.5%
VERACYTE INC38Q3 20231.5%
LAM RESEARCH CORP35Q3 20233.4%
XPO LOGISTICS INC34Q1 20233.8%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.6%
MAGNA INTL INC33Q4 20212.5%

View Eventide Asset Management's complete holdings history.

Latest significant ownerships (13-D/G)
Eventide Asset Management Q1 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%

View Eventide Asset Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-20
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Eventide Asset Management's complete filings history.

Compare quarters

Export Eventide Asset Management's holdings